We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs.
- Authors
Neogi, Ujjwal; Hill, Kyle J.; Ambikan, Anoop T; Heng, Xiao; Quinn, Thomas P.; Byrareddy, Siddappa N.; Sönnerborg, Anders; Sarafianos, Stefan G.; Singh, Kamal
- Abstract
Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.
- Subjects
MERS coronavirus; RNA polymerases; SARS-CoV-2; CORONAVIRUS diseases; COVID-19; SARS virus
- Publication
Pathogens, 2020, Vol 9, Issue 5, p320
- ISSN
2076-0817
- Publication type
Article
- DOI
10.3390/pathogens9050320